An2 Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Almitas Capital LLC has reported a decreased ownership stake in AN2 Therapeutics, Inc., now holding 4.1% of the company's common stock.
NASDAQ
Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in AN2 Therapeutics, Inc., comprising common stock and pre-funded warrants.
NASDAQ
Millennium Management LLC and affiliated entities have reported a collective beneficial ownership of 6.3% in AN2 Therapeutics, Inc. common stock.
NASDAQ
Vivo Opportunity Fund Holdings and affiliates report an aggregate passive ownership of 8.8% in AN2 Therapeutics, Inc. common stock.
NASDAQ
Almitas Capital LLC has reported a 5.2% beneficial ownership stake in AN2 Therapeutics, Inc., holding 1,428,323 shares of common stock and warrants.
NASDAQ
Coastlands Capital LP and its affiliated entities have disclosed a passive beneficial ownership of 9.3% of AN2 Therapeutics, Inc.'s common stock.
NASDAQ
Adjuvant Global Health Technology Fund, L.P. and its related entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 7.9% of AN2 Therapeutics, Inc.'s common stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: RA Capital Management Divests Entire Stake in AN2 Therapeutics, Filing Shows 0% Beneficial Ownership
An amended Schedule 13G filing reveals that RA Capital Management and its affiliates have fully divested their beneficial ownership in AN2 Therapeutics, Inc., now holding 0% of the common stock.
NASDAQ
SCHEDULE 13G/A: TCG Crossover Entities Fully Divest Stake in AN2 Therapeutics
TCG Crossover GP I, LLC, TCG Crossover Fund I, L.P., and Chen Yu have reported a complete divestment of their beneficial ownership in AN2 Therapeutics, Inc., reducing their stake to 0% as of December 31, 2024.
NASDAQ
Brii Biosciences Limited has filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.1% in AN2 Therapeutics, Inc. as of December 31, 2024.
NASDAQ
Frazier Life Sciences Public Fund and affiliated entities have reported a complete divestment of their beneficial ownership in AN2 Therapeutics, Inc. common stock as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Insider Eric Easom Discloses 6.2% Stake in AN2 Therapeutics
Eric Easom, a U.S. citizen, has reported beneficial ownership of 6.2% of AN2 Therapeutics, Inc.'s common stock as of December 31, 2024, through a Schedule 13G Amendment No. 1 filing.
NASDAQ
BML Investment Partners, L.P. has filed an amended Schedule 13G, revealing a substantial 19.2% beneficial ownership stake in AN2 Therapeutics, Inc. as of December 31, 2024.